Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 1/2015

01-03-2015 | HIV Pathogenesis and Treatment (AL Landay, Section Editor)

Enhancing Our Understanding of Current Therapies for Hepatitis C Virus (HCV)

Authors: Neliswa A. Gogela, Ming V. Lin, Jessica L. Wisocky, Raymond T. Chung

Published in: Current HIV/AIDS Reports | Issue 1/2015

Login to get access

Abstract

Great progress has been made in understanding the HCV genome and its molecular virology. This understanding has culminated in the development of direct-acting antiviral (DAA) agents targeting HCV viral proteins. Telaprevir (TVR) and boceprevir (BOC) were the first DAAs introduced for treatment of genotype 1 HCV in 2011; when used in combination with pegylated interferon (pegIFN) and ribavirin (RBV), these protease inhibitors improved efficacy in patients with chronic HCV infection compared to the traditional dual therapy. However, this combination was associated with adverse events that often led to early termination of therapy. In late 2013, the FDA approved a second wave of DAAs, sofosbuvir (SOF) and simeprevir (SMV). The use of SOF with SMV opened the door for IFN-free combination regimens. This combination was highly efficacious and well tolerated in patients with HCV genotype 1. Sofosbuvir and ledipasvir (LDV) fixed-dose oral combination (FDC) therapy, and paritaprevir/ritonavir, ombitasvir and dasabuvir ± RBV were recently approved, elevating sustained virologic response (SVR) rates to over 95 %. We are anticipating the approval of additional IFN-free regimens with comparable efficacy and tolerability but with the addition of pangenotypic coverage, fewer drug-drug interactions, and a high barrier to resistance. This review will summarize current management for chronic HCV infection.
Literature
1.
Chevaliez, S. and J.M. Pawlotsky, HCV genome and life cycle, in hepatitis C viruses: genomes and molecular biology, S.L. Tan, Editor. 2006: Norfolk (UK).
2.
Choo QL et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244(4902):359–62.CrossRefPubMed
3.
Urbanus AT et al. Trends in hepatitis C virus infections among MSM attending a sexually transmitted infection clinic; 1995–2010. AIDS. 2014;28(5):781–90.CrossRefPubMed
4.
Zielinski A. Sexual behaviour and the risk of HCV infection. Przegl Epidemiol. 2014;68(1):1–3. 99–100.PubMed
5.
Smith BD et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep. 2012;61(RR-4):1–32.PubMed
6.
7.
Armstrong GL et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705–14.CrossRefPubMed
8.
Data Collection on Adverse Events of Anti, H.I.V.d.S.G., et al.. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS, 2010. 24(10): p. 1537–48.
9.
Davis GL et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138(2):513–21. 521 e1-6.CrossRefPubMed
10.
Lee MH et al. Epidemiology and natural history of hepatitis C virus infection. World J Gastroenterol. 2014;20(28):9270–80.PubMedCentralPubMed
11.
Konerman MA et al. Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs. Hepatology. 2014;59(3):767–75.CrossRefPubMedCentralPubMed
12.
13.
Thein HH et al. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS. 2008;22(15):1979–91.CrossRefPubMed
14.
15.
Dorner M et al. Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Nature. 2013;501(7466):237–41.CrossRefPubMed
16.
Schaefer EA, Chung RT. Anti-hepatitis C virus drugs in development. Gastroenterology. 2012;142(6):1340–50. e1.CrossRefPubMed
17.
18.
DeLemos AS, Chung RT. Hepatitis C treatment: an incipient therapeutic revolution. Trends Mol Med. 2014;20(6):315–21.CrossRefPubMed
19.
20.
Liver, E.A.f.S.o., EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol, 2014. 60(2): p. 392–420.
21.
Manns MP et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958–65.CrossRefPubMed
22.
Jia Z et al. Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis. PLoS One. 2012;7(9):e45698.CrossRefPubMedCentralPubMed
23.
24.
Shoeb D et al. Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trial. J Hepatol. 2014;60(4):699–705.CrossRefPubMed
25.
El Makhzangy H, Esmat G, Said M, Elraziky M, Shouman S, Refai R, et al. Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. J Med Virol. 2009;81(9):1576–83. doi:10.​1002/​jmv.​21570.
26.
Derbala M, Amer A, Bener A, Lopez AC, Omar M, El Ghannam M. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. J Viral Hepat. 2005;12(4):380–5.
27.
American Association for the Study of Liver disease, I.D.S.o.A.a.I.A.S.-U. American Association for the Study of Liver Disease, Infectious Diseases Society of America and International Antiviral Society-USA. Recommendations for testing, managing, and treating hepatitis C. 2014 [cited 2014 October 29].
28.
29.••
Lawitz, E., et al., Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet, 2014. COSMOS: This study evaluated a combination of sofosbuvir and simeprevir for treatment of HCV GT1 infected individuals. Cohort 1 consisted of treatment naive patients with F3-F4 fibrosis and cohort 2 consisted of treatment experienced (previous null responders to pegIFN and RBV while previous PI use was a contraindication). SVR rates were >90 % in both cohorts and this treatment combination was efficacious and well tolerated.
30.
Palanisamy N et al. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in hepatitis C virus genotypes 1a, 2b and 3a. Antiviral Res. 2013;99(1):12–7.CrossRefPubMed
31.
Lawitz, E.G., E.; Pearlman, B.; Tam, E.; Ghesquierre, W.; Guyader, D.; Alric, L.; Bronowicki, J.; Lester, L.; Sievert, w.; Ghalib, R.; Balart, L.; Sund, F.; Lagging, M.; Dukto,.F.; Shaughnessy, M.; Hwang, P.; Howe, A. Y. M.; Wahl, J.; Robertson, M.; Barr, E.; Harber, B. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK −5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open label phase 2 trial. Lancet, 2014.
32.
Macias J et al. Latest pharmacotherapy options for treating hepatitis C in HIV-infected patients. Expert Opin Pharmacother. 2014;15(13):1837–48.CrossRefPubMed
33.•
Zeuzem S et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1604–14. SAPPHIRE II: Retreatment with ABT-450, ombitasvir, dasabuvir and ribavirin produced high SVR rates (95.2%) in previous null responders.
34.•
Poordad F et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370(21):1973–82. TURQOISSE II: A combination of ABT-450, ombitasvir, dasabuvir and ribavirin produced high SVR rates even in patients with cirrhosis. None of them had decompensation, only side effects reported were fatigue and nausea.
35.
Yau AH, Yoshida EM. Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review. Can J Gastroenterol Hepatol. 2014;28(8):445–51.PubMedCentralPubMed
36.
Lawitz, E.O.R., W. D.; Freilich, B. L.; Box, T. D.; Overcash, S.; Liu, W.; Campbell, A. L.; Lin, C.; Asatryan, A.; Kort, J, Potent antiviral activity of ABT-493 and ABT-530 with 3-day monotherapy in patients with or without cirrhosis in phase 2 and 3 studies. AASLD 2014 Abstract, 2014.
37.
Schinazi R et al. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int. 2014;34 Suppl 1:69–78.CrossRefPubMed
38.
Muir AJ. The rapid evolution of treatment strategies for hepatitis C. Am J Gastroenterol. 2014;109(5):628–35. quiz 636.CrossRefPubMed
39.
40.••
Afdhal N et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483–93. ION II: This study evaluated a fixed dose combination of sofosbuvir and ledipasvir with or without ribavirin in treatment experienced patients infected with GT1. A total of 440 patients were recruited, 20% had cirrhosis and 79% were infected with GT1a. SVR rates varied from 94%–99%, and 99% was observed in the 2 groups that received treatment for 24 weeks.CrossRefPubMed
41.••
Afdhal N et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889–98. ION I: This study evaluated a fixed dose combination of sofosbuvir and ledipasvir with or without ribavirin in treatment naive patients infected with GT1. Total number of patients recruited was 865 of which 12% had cirrhosis, 12% black and 67% GT1a. Patients were randomly assigned in a 1:1:1:1 ratio and were stratified according to HCV genotype (1a or 1b) and cirrhosis to receive treatment for either 12 or 24 weeks. Except for 1 patient who experienced virological breakthrough from non compliance this combination had SVR rates of 97%–99% across all four arms. The few patients that relapsed were older males with cirrhosis.CrossRefPubMed
42.•
Feld JJ et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1594–603. SAPPHIRE I: In this study a total of 631 previously untreated patients infected with HCV genotype 1 were randomized to receive an active regimen that consisted of ABT-450/r, ombitasvir, dasabuvir and ribavirin for group A and matching placebos for group B. SVR rates were 96.2% in group A and when genotype 1 was subtype GT1b had highest SVR rates of 98%.
43.•
Ferenci P et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370(21):1983–92. PEARL III and IV: A combination of ABT-450/r, ombitasvir, dasabuvir with or without ribavirin produced highest SVR rates (99.5%) among previously untreated patients infected with GT1b compared to GT1a (97%). Among patients infected with GT1a the rate of virological failure was higher ribavirin free arm (7.8% vs. 2.0%).
44.
45.••
Sulkowski MS et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211–21. A combination of daclatasvir and sofosbuvir was evaluated amongst patients infected with HCV GT1-3. Majority of the patients in this study were infected with GT1 (both treatment naive and previous PI failures) and only 18 had GT3. This combination proved highly efficacious and was well tolerated.CrossRefPubMed
46.
Stedman CA. Current prospects for interferon-free treatment of hepatitis C in 2012. J Gastroenterol Hepatol. 2013;28(1):38–45.CrossRefPubMed
47.
Gane, E.H., R.H.; McNally, J., Svarovskaia, E.; Brainard,D. M.; Symonds, W. T.; McHutchison, J. G.; Stedman, C, Once-daily sofosbuvir with GS-5816 for 8 weeks with or without ribavirin in patients with HCV genotype 3 without cirrhosis results in high rates of SVR: the ELECTRON-2 Study. AASLD 2014 Abstract, 2014.
48.
Zeuzem S et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370(21):1993–2001.CrossRefPubMed
49.••
Kowdley KV et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879–88. ION III: This study evaluated a fixed dose combination of sofosbuvir and ledipasvir with or without ribavirin in treatment naive patients without cirrhosis infected with GT1. Patients were randomly assigned to receive treatment for either 8 or 12 weeks. SVR rate in the 12 week arm was one percent higher than in the 8 week arm (95% vs. 94%), and ribavirin had no added benefits.
50.
Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147:359–65.
51.
Jacobson IM et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867–77.CrossRefPubMed
52.
Koff RS. Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2014;39(5):478–87.CrossRefPubMed
53.
Everson GT et al. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology. 2014;146(2):420–9.CrossRefPubMed
54.
Asselah T. Sofosbuvir-based interferon-free therapy for patients with HCV infection. J Hepatol. 2013;59(6):1342–5.CrossRefPubMed
55.
Lawitz, E., et al., Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology, 2014.
56.
Heidrich, B., P1109 Overtreatment of patients with chronic hepatitis C (CHC) genotype 2/3 with low baseline viral load and RVR: experiences in a real world. Journal of Hepatology, 2014. 60(1).
57.
Gane, E.H., R.H.; An, D.; Pang, P. S.; Symonds, W. T.; McHutchison, J. G.; Stedman, C. Ledipasvir/sofosbuvir fixed-dose combination is safe and effective in difficult-to-treat populations including GT 3 patients, decompensated GT 1 patients, and GT 1 patients with prior sofosbuvir experience. EASL - The International Liver Congress 2014, 2014.
58.
Kapoor, R.K., A.; Sidharthan, S.; Sims, Z.; Petersen, T. L.; Osinusi, A.; Nelson, A. K.; Silk, R.; Kotb, C.; Sugarman, K.; Lam, B. P.; Pang, P. S.; Subramanian, M.; McHutchinson, J. G.; Masur, H .; Kottilil, S.; Rustgi, V. D., Treatment of hepatitis C genotype 4 with ledipasvir and sofosbuvir for 12 weeks: results of the SYNERGY trial. American Association for the Study of Liver Diseases (AASLD) Liver Meeting., 2014.
59.
Pol, S.R., K. R.; Baykal, T.; Hezode, C.; Hassanein, T.; Marcellin, P.; Berenguer, M.; Fleischer-Stepniewska, K. M.; Hall, C.; Collins, C.; Vilchez, R. A. Interferon-free regimens of ombitasvir and ABT-450/r with or without ribavirin in patients with HCV genotype 4 infection: PEARL-I Study results. American Association for the Study of Liver Diseases (AASLD) Liver Meeting., 2014.
60.
Lawitz E, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;369(7):678–9.
61.
Degasperi E, Aghemo A. Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives. Hepatol Med. 2014;6:25–33.
62.
Gane, E.H., R.H.; An, D.; An, D.; Svaroskaia, E. S.; Pang, P. S.; Symonds, W. T.; McHutchison, J. G.; Stedman, C. High efficacy of LDV/SOF regimens for 12 weeks for patients with HCV GT3 or GT6 infection. American Association for the Study of Liver Diseases (AASLD) Liver Meeting., 2014.
63.
Manns M et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2014;384(9941):414–26.CrossRefPubMed
64.
Esmat GE, Shiha G, Omar RF et al. Sofosbuvir plus ribavirin in the treatment of Egyptian patients with chronic genotype 4 HCV infection. 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Abstract 959., 2014.
65.
van der Meer AJ, Hansen BE, Janssen HL. Sustained virological response to treatment in patients with chronic hepatitis C—reply. JAMA. 2013;309(14):1457.CrossRefPubMed
66.
Shire NJ, Welge JA, Sherman KE. Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis. J Viral Hepat. 2007;14(4):239–48.CrossRefPubMed
67.
Sulkowski MS et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med. 2013;159(2):86–96.PubMed
68.••
Osinusi A, T.K., Nelson A, Kohli A, Gross C, Polis MA, Pang PS, Symonds WT, Talwani R, Sajadi MM, Hogan J, Benator D, Subramanian M, Mchutchison J, Masur H, Kottilil S. for the NIAID ERADICATE Study Team, Use of sofosbuvir/ledipasvir fixed dose combination for treatment of HCV genotype-1 in patients coinfected with HIV. Journal of Hepatology, 2014;60(1): p. S7. ERADICATE: This study evaluated use of sofosbuvir and ledipasvir in patients with HIV and HCV GT1 coinfection. A total of 50 patients (80% with GT1a) majority on ART and few (20%) not on ART but with reserved CD4 of >500 cells/mm 3. All patients on ART were on tenofovir/emtricitabine, 41% were on efavirenz, 27% raltegravir and 21% on rilpivirine. 100% SVR12 rates were observed in the untreated group and 100% SVR4 in the ART group. No adverse events reported thus far.
69.••
Sulkowski M, E.J., Wyles D, Trinh R, Lalezari J, Slim J, Gathe J, Ruane PJ, Wang C, Elion R, Bredeek F, Brennan R, Blick G, Khatri A, Gibbons K, Hu YB, Fredrick L, Pilot-Matias T, Da Silva-Tillmann, McGovern BB, Campbell AL, Podsadecki T. TURQUOISE-I: safety and efficacy of ABT-450/r/ombitasvir, dasabuvir, and ribavirin in patients co-infected with hepatitis C and HIV-1. International AIDS conference, 2014. TURQUOISE-1: This study has evaluated the safety and efficacy of ABT-450 /r/ombitasvir, dasabuvir and ribavirin in HIV/HCV-1 co-infected individuals. A total number 63 individuals, majority males (92.1 %), white race (76.2), GT1a (88.9 %), 19 % had cirrhosis and a few (33.3 %) were previously treated. SVR 4 for the 12 week arm was 96.8 % and EOTR for the 24 week arms was 96.7 %. No adverse events reported thus far. ART regimen used consisted of atazanavir or raltegravir.
70.
Baid-Agrawal S et al. Hepatitis C virus infection and kidney transplantation in 2014: what’s new? Am J Transplant. 2014;14(10):2206–20.CrossRefPubMed
71.
Fabrizi F, Messa P, Martin P. Recent advances on hepatitis C virus in dialysis population. Kidney Blood Press Res. 2014;39(4):260–71.PubMed
72.
Liu CH et al. Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Ann Intern Med. 2013;159(11):729–38.CrossRefPubMed
73.
Gane EJ, Agarwal K. Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: “a flood of opportunity”. Am J Transplant. 2014;14(5):994–1002.CrossRefPubMed
74.
Samuel, D.C., M.; Gane, E et al., Sofosbuvir and ribavirin for the treatment of recurrent hepatitis C infection after liver transplantation: results of a prospective, multicenter study. 49th European Association for the Study of the Liver International Liver Congress (EASL 2014). London, 2014.
75.
Reddy, K.R.E., G.T.; Flamm, S. L.; Denning, J. M.; Arteburn, S.; Brandt-Sarif, T.; Pang, P. S.; McHutchinson, J. G.; Curry, M. P.; Charlton, M., Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with post transplant recurrence: preliminary results of a prospective study. AASLD 2014 Abstract, 2014.
76.
73. Kwo, P.Y., et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med, 2014.
Metadata
Title
Enhancing Our Understanding of Current Therapies for Hepatitis C Virus (HCV)
Authors
Neliswa A. Gogela
Ming V. Lin
Jessica L. Wisocky
Raymond T. Chung
Publication date
01-03-2015
Publisher
Springer US
Published in
Current HIV/AIDS Reports / Issue 1/2015
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-014-0243-7

Other articles of this Issue 1/2015

Current HIV/AIDS Reports 1/2015 Go to the issue

The Science of Prevention (JD Stekler, Section Editor)

A Systematic Review of Recent Smartphone, Internet and Web 2.0 Interventions to Address the HIV Continuum of Care

HIV Pathogenesis and Treatment (AL Landay, Section Editor)

Using the Pathogenic and Nonpathogenic Nonhuman Primate Model for Studying Non-AIDS Comorbidities

HIV Pathogenesis and Treatment (AL Landay, Section Editor)

Understanding Frailty, Aging, and Inflammation in HIV Infection

HIV Pathogenesis and Treatment (AL Landay, Section Editor)

Human Papillomavirus in the HIV-Infected Host: Epidemiology and Pathogenesis in the Antiretroviral Era

HIV Pathogenesis and Treatment (AL Landay, Section Editor)

Human Immunodeficiency Virus (HIV)-1 Integration Sites in Viral Latency

The Science of Prevention (JD Stekler, Section Editor)

Antiretrovirals for Primary HIV Prevention: the Current Status of Pre- and Post-exposure Prophylaxis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits